# Bausch + Lomb Corporation (BLCO): Investor Outlook and Potential 15.62% Upside in the Healthcare Sector

- Link: https://www.directorstalkinterviews.com/bausch-lomb-corporation-blco-investor-outlook-and-potential-15-62-upside-in-the-healthcare-sector/4121253247
- Published: 2026-06-08T10:22:41+01:00
- Author: Madison Wilson

Bausch + Lomb Corporation (NYSE: BLCO), a venerable name in the healthcare sector,
is capturing investor attention with a potential upside of 15.62%, as analysts project
the stock to reach an average target price of $17.88. As a leading player in the
medical instruments and supplies industry, the Canadian-based company has a market
capitalization of $5.51 billion and operates as a subsidiary of Bausch Health Companies
Inc.

The company’s current stock price stands at $15.46, with a relatively narrow 52-
week range of $11.55 to $18.60. The slight price change of 0.11 (0.01%) underscores
a stable market perception, yet the stock trades below both its 50-day and 200-day
moving averages of $16.02 and $16.11, respectively. With an RSI of 65.65, Bausch
+ Lomb is nearing the overbought territory, which may signal potential volatility
ahead.

A standout among Bausch + Lomb’s financial metrics is its revenue growth of 9.40%.
However, the company faces challenges, as indicated by a negative EPS of -0.62 and
a return on equity of -3.28%. The absence of P/E and PEG ratios suggests that the
stock might be undervalued, further supported by the lack of a dividend yield and
payout ratio. Despite these hurdles, Bausch + Lomb’s free cash flow of $238.5 million
presents a silver lining, hinting at the company’s ability to invest in growth opportunities
or manage its debt effectively.

Analysts have issued mixed ratings on the stock: 5 buy, 7 hold, and 1 sell. This
diversity in opinion reflects the nuanced view of Bausch + Lomb’s current market
position. The target price range of $16.00 to $21.00 indicates varying degrees of
optimism among analysts, yet the average target suggests room for appreciation.

The company’s operations are segmented into Vision Care, Pharmaceuticals, and Surgical,
offering a comprehensive portfolio of eye health products and services across international
markets. This diversification allows Bausch + Lomb to tap into multiple revenue 
streams, ranging from contact lenses and eye care products to pharmaceutical treatments
and surgical instruments.

As Bausch + Lomb continues to build on its long-standing reputation, investors should
monitor its strategic initiatives, particularly in expanding its international footprint
and enhancing its product offerings. The company’s ability to innovate and capture
market share in the growing eye health sector will be crucial in realizing the potential
upside highlighted by analysts.

In navigating the investment landscape, potential investors should weigh the company’s
solid market presence and growth prospects against the backdrop of its current financial
challenges. Bausch + Lomb’s rich history and strategic positioning in the healthcare
sector make it a compelling consideration for those looking to diversify their portfolios
with a focus on medical instruments and supplies.

Share on: